<!doctype html><html lang="zh-hans"><head><meta charset="utf-8"><meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no"><title>五个新出现的冠状病毒变异中最令人担忧的突变 The Most Worrying Mutations in Five Emerging Coronavirus Variants</title><link rel="stylesheet" href="https://stackpath.bootstrapcdn.com/bootstrap/4.3.1/css/bootstrap.min.css" integrity="sha384-ggOyR0iXCbMQv3Xipma34MD+dH/1fQ784/j6cY/iJTQUOhcWr7x9JvoRxT2MZw1T" crossorigin="anonymous"><link rel="stylesheet" href="/img/css.css?random="><link data-rh="true" rel="icon" href="/img/favicon.ico"/><script data-ad-client="ca-pub-6067137220025946" async src="https://pagead2.googlesyndication.com/pagead/js/adsbygoogle.js"></script><script type="text/javascript" src="https://platform-api.sharethis.com/js/sharethis.js#property=5effb96910009800120b8d4d&product=inline-share-buttons" async="async"></script>
<script>var _hmt = _hmt || [];(function() {var hm = document.createElement("script");hm.src = "https://hm.baidu.com/hm.js?03c1a0f31299b4a2fbb83c34d6beaac9";var s = document.getElementsByTagName("script")[0]; s.parentNode.insertBefore(hm, s);})();</script></head><body><div id="my_header"><div class="container"><nav class="navbar navbar-expand-lg"><a class="navbar-brand" href="/"><img alt="diglog" src="/img/logo.v1.gif" class="rounded-sm"></a><button class="navbar-toggler" type="button" data-toggle="collapse" data-target="#navbarNavAltMarkup" aria-controls="navbarNavAltMarkup" aria-expanded="false" aria-label="Toggle navigation"><span class="navbar-toggler-icon"></span></button><div class="collapse navbar-collapse" id="navbarNavAltMarkup"><div class="navbar-nav"></div></div></nav></div></div><div class="container"><div id="my_content"><h1 class="page_narrow">The Most Worrying Mutations in Five Emerging Coronavirus Variants<br/>五个新出现的冠状病毒变异中最令人担忧的突变 </h1><div class="row"><div class="col-lg-12 col-12"><div class="my_story_list_item shadow p-3 mb-5 bg-white rounded"><div class="story_page_pub_time page_narrow">2021-02-27 10:44:29</div><div class="story_img_container"><a href="http://img2.diglog.com/img/2021/2/0cecf7484b58727d79e929d30958a553.jpg"><img src="http://img2.diglog.com/img/2021/2/0cecf7484b58727d79e929d30958a553.jpg" class="img-fluid my_story_img" onerror="this.style.display='none'"></a></div><div class="page_narrow text-break page_content"><p>When the coronavirus SARS-CoV-2 burst upon the world last winter, scientists knew it was bad. But they also thought it was stable. Coronaviruses do not mutate as readily as the viruses that cause the flu, hepatitis or AIDS, for instance—thanks in part to a molecular “proofreading” system that SARS-CoV-2 and its kin use to prevent damaging genetic errors when replicating.</p><p>去年冬天，当冠状病毒SARS-CoV-2在世界上爆发时，科学家们知道这很糟糕。但是他们也认为它是稳定的。冠状病毒的变异不像引起流感，肝炎或艾滋病的病毒那样容易突变，这部分归功于SARS-CoV-2及其亲缘分子的分子“校对”系统，以防止复制时破坏性遗传错误。</p><p> Researchers were only partly right. The virus is indeed bad—but it is not so stable after all. SARS-CoV-2 has been acquiring minor random mutations ever since it jumped from animals to humans. These mutations can take the form of single-letter typos in the viral genetic code or deletions or insertions of longer stretches. When they occur, most mutations either kill the virus or cause no change in its structure or behavior.</p><p> 研究人员只是部分正确。该病毒确实很糟糕，但毕竟不稳定。自从SARS-CoV-2从动物转移到人类以来，它一直在获得较小的随机突变。这些突变可以采取病毒遗传密码中单字母错别字的形式，也可以采用更长片段的缺失或插入形式。当它们发生时，大多数突变要么杀死病毒，要么不改变其结构或行为。</p><p> But in recent months, several new variants of the original virus (also called the wild type) have been spotted that appear to cause  major changes in the way the pathogen acts, including alterations to its contagiousness. These viral versions have seemingly popped up in rapid succession in different geographical regions, such as the U.K., South Africa and Brazil, and in some cases have outcompeted the existing variants. Although improved surveillance and sequencing efforts might partly explain why these variants are appearing now, some repetition in their patterns suggest the mutations are not random.</p><p> 但是在最近几个月中，发现了原始病毒的几种新变种（也称为野生型），它们似乎导致病原体的行为方式发生了重大变化，包括其传染性的改变。这些病毒版本似乎在英国，南非和巴西等不同地理区域迅速出现，并且在某些情况下胜过了现有的变体。尽管改进的监视和测序工作可能部分解释了为什么现在出现这些变体，但其模式的某些重复表明这些突变不是随机的。</p><p> “What we’re seeing is similar mutations arising in multiple places,” says Adam Lauring, a virologist at the University of Michigan. “That’s pretty suggestive that these mutations are doing something.”</p><p> 密歇根大学的病毒学家亚当·劳林（Adam Lauring）说：“我们看到的是类似的突变在多个地方产生。” “这很暗示这些突变正在起作用。”</p><p> Specifically, they appear to help the virus transmit more readily and evade the immune system. This month researchers reported, for the first time, that antibodies from individuals with COVID did not completely neutralize a variant first identified in South Africa. A few people who recovered from the disease also appear to have been reinfected with the mutant virus.</p><p> 具体而言，它们似乎有助于病毒更容易地传播并逃避免疫系统。本月研究人员首次报告，来自COVID个体的抗体并未完全中和南非首次发现的变体。从这种疾病中恢复过来的一些人似乎也已被突变病毒重新感染。</p><p> Thus far, vaccines made by Moderna and Pfizer seem to work against the new variants, although Moderna has begun developing a booster shot specific to new variants. Because these two vaccines are more than 90 percent effective, a slight drop in effectiveness would still make them worth using, experts say.</p><p> 迄今为止，尽管Moderna已开始开发针对新变种的加强注射，但Moderna和Pfizer生产的疫苗似乎可以对抗新变种。专家说，由于这两种疫苗的有效性均超过90％，因此有效性略有下降仍将使它们值得使用。</p><p> “I’m optimistic this won&#39;t compromise the [COVID vaccines], but obviously, it’s something we’ve got to watch closely,” Lauring says. In coming years, he adds, companies may need to retool these vaccines and administer updated versions, much in the same way that flu vaccines are revised each year. Most vaccines cause a much stronger immune reaction than a natural infection with a virus. And in clinical trials for its vaccine, Moderna found that the antibodies produced after vaccination may  last longer than those naturally produced after SARS-CoV-2 infection.</p><p> 劳林说：“我很乐观，这不会影响[COVID疫苗]，但显然，我们必须密切注意这一点。”他补充说，在未来的几年中，公司可能需要重新改造这些疫苗并管理更新的版本，这与每年修订流感疫苗的方式大同小异。与自然感染病毒相比，大多数疫苗引起的免疫反应要强得多。在其疫苗的临床试验中，Moderna发现，接种疫苗后产生的抗体可能比SARS-CoV-2感染后自然产生的抗体持续时间更长。 </p><p> Here are five of the most prominent variants, listed in the order that researchers first spotted them. This roster identifies where each variant was first seen and gives the technical name or names scientists use to identify it. (Naming variants has caused some confusion because different research teams employ different systems. This list uses one  based on the ancestral lineage of each variant, but some variants still have more than one name). The entries also highlight important mutations in each variant—denoted by letters and numbers that indicate their position in the sequence of the viral genome—and describe what scientists know or suspect about what those changes do.</p><p>以下是五个最突出的变体，按照研究人员首先发现它们的顺序列出。该花名册确定了每个变体的首次出现位置，并提供了科学家用来识别它的一个或多个技术名称。 （由于不同的研究团队采用不同的系统，命名变体引起了一些混乱。此列表基于每个变体的祖先血统使用了一个列表，但是某些变体仍然具有多个名称）。条目还突出显示了每个变体中的重要突变（用字母和数字表示，表明它们在病毒基因组序列中的位置），并描述了科学家对这些变化的了解或怀疑。</p><p>    The 20A.EU1 variant, first identified in Spain, contains a mutation called A222V on the viral spike protein. The spike is a component of SARS-CoV-2 that binds to a receptor on human cells called ACE2, and this attachment helps the virus get inside those cells and infect them. The spike protein is also the part of the pathogen that is targeted by human antibodies when they fight back against the infection. In lab tests, human antibodies were slightly less effective at neutralizing viruses with the A222V mutation. Over the course of several months, the 20A.EU1 variant  became the dominant one in Europe. Epidemiologists never saw any evidence that it was more transmissible than the original, however. Researchers believe that when Europe began lifting travel restrictions last summer, the variant that was dominant in Spain spread across the continent.</p><p>    在西班牙首次发现的20A.EU1变体在病毒刺突蛋白上包含一个称为A222V的突变。尖峰是SARS-CoV-2的一个组成部分，可与人类细胞上称为ACE2的受体结合，这种附着有助于病毒进入这些细胞内并对其进行感染。当人抗体抵抗感染时，刺突蛋白也是病原体的一部分，而人抗体则将其作为靶标。在实验室测试中，人抗体在中和具有A222V突变的病毒方面效果稍差。在几个月的时间里，20A.EU1变体成为欧洲的主要变体。流行病学家从未见过任何证据表明它比原始病毒更易传播。研究人员认为，当欧洲去年夏天开始取消旅行限制时，在西班牙占主导地位的变体遍布整个非洲大陆。</p><p>    Scientists in the U.K. had been watching the B.1.1.7 variant for some time before announcing in December that it might be at least 50 percent more transmissible than the original form. That announcement was based on epidemiological data that showed the virus rapidly spreading throughout the nation. And it led to international travel bans and stronger lockdown measures in the U.K.</p><p>    英国的科学家一直在观察B.1.1.7变体已有一段时间，然后在12月宣布它的可传播性可能比原始形式高出至少50％。该声明是基于流行病学数据显示的，该病毒在全国范围内迅速传播。这导致了国际旅行禁令和英国更严格的封锁措施。</p><p> The B.1.1.7 variant contains 17 mutations, including several in the spike protein. One of them, N501Y, has been found to help the virus  bind more tightly to the ACE2 cellular receptor. It is unclear, however, whether the variant’s enhanced contagiousness comes from N501Y alone or also involves some combination of other spike protein mutations.</p><p> B.1.1.7变体包含17个突变，包括尖峰蛋白中的几个突变。已发现其中之一N501Y可帮助病毒更紧密地与ACE2细胞受体结合。但是，尚不清楚该变体的增强的传染性是否仅来自N501Y还是还涉及其他刺突蛋白突变的某种组合。</p><p> Despite initial concerns, there has been no real evidence that the variant is more infectious in children than the original, says University of Cambridge microbiologist Sharon Peacock, who is executive director of the COVID-19 Genomics UK (COG-UK) Consortium, a group that analyzes genetic changes to the virus. Both Pfizer and Moderna believe that their COVID-19 vaccines will still work against B.1.1.7. Recent  data from the U.K. hint that the variant may be more lethal than the original, but the analyses are preliminary.</p><p> 剑桥大学微生物学家莎伦·皮科克（Sharon Peacock）表示，尽管最初有人担心，但该变体在儿童中的传染性比原始变种高，他是英国COVID-19基因组学（COG-UK）联合会的执行董事。分析病毒的遗传变化。辉瑞和Moderna都认为他们的COVID-19疫苗仍然可以对抗B.1.1.7。英国的最新数据表明，该变体可能比原始变体更具杀伤力，但分析只是初步的。</p><p> B.1.1.7 does stand out because it accumulated so many mutations, apparently all at once. Lauring and others suspect that these mutations may have arisen within one immunocompromised patient who was infected for a long time because that person was unable to fight off the virus. It is likely that only a few of these changes gave the variant an evolutionary advantage and allowed it to quickly spread around the U.K., says Scott Weaver, a microbiologist at the University of Texas Medical Branch at Galveston. The others were simply along for the ride.</p><p> B.1.1.7之所以能够脱颖而出，是因为它积累了很多突变，显然是一次突变。 Lauring和其他人怀疑这些突变可能是由于长期无法抵抗病毒的一名感染免疫力低下的患者而引起的。加尔维斯顿德州大学医学分校的微生物学家斯科特·韦弗（Scott Weaver）说，这些变化中只有很少的变化使该变体具有进化优势，并使其能够在英国迅速传播。其他人只是顺路兜风。</p><p>    The B.1.351 variant appeared around the same time as B.1.1.7, and it spread quickly in South Africa to become the dominant version in that country. Like its European counterpart, B.1.351 contains the N501Y mutation, although evidence seems to suggest the two variants arose independently. But scientists are more concerned about another mutation called E484K that appears in the South African version. The genetic change may help the virus evade the immune system and vaccines.</p><p>    B.1.351变种与B.1.1.7大约同时出现，并且在南非迅速传播，成为该国的主要版本。像其欧洲同类产品一样，B.1.351包含N501Y突变，尽管证据似乎表明这两个变体是独立出现的。但是科学家们更担心出现在南非版本中的另一种称为E484K的突变。基因改变可能有助于病毒逃避免疫系统和疫苗。 </p><p> Using yeast cells, evolutionary and computational biologist Jesse Bloom of the Fred Hutchinson Cancer Research Center in Seattle and his lab  created a series of spike proteins with almost all of the more than 3,800 possible protein component changes that could be driven by genetic mutations. Then the scientists tested how well or poorly human antibodies bound to each altered spike. They found that E484K—as well as similar mutations at that particular spot in the protein—made it as much as 10 times more difficult for antibodies to bind to the spike in some people. Bloom’s lab  also found that some antibody cocktails, such as one currently being tested by the drug and biotech companies Regeneron and Eli Lilly, may be less effective against mutations present in the B.1.351 variant.</p><p>西雅图弗雷德·哈钦森癌症研究中心的进化和计算生物学家杰西·布鲁姆（Jesse Bloom）和他的实验室使用酵母细胞，创建了一系列刺突蛋白，几乎具有3800多种可能由遗传突变驱动的蛋白质成分变化。然后，科学家测试了人类抗体与每个变化的峰结合的好坏。他们发现，E484K以及该蛋白质特定位置的类似突变，使抗体与某些人的刺突结合的难度增加了10倍之多。 Bloom的实验室还发现，某些抗体混合物，例如目前正在由药物和生物技术公司Regeneron和Eli Lilly测试的一种抗体混合物，对B.1.351变体中存在的突变可能无效。</p><p> Late this month researchers in South Africa released a preprint study (research that has not yet been peer-reviewed) showing that an antibody-containing serum from COVID patients was  considerably less effective at neutralizing this variant. And in another preliminary preprint posted on January 26, scientists reported they put B.1.351 into serum taken from people who had been vaccinated with either the Pfizer or Moderna vaccine. They found  antibodies in that serum showed reduced neutralizing activity against the mutant, compared with their activity against the original virus.</p><p> 本月晚些时候，南非的研究人员发布了一项预印本研究（尚未经过同行评审的研究），结果显示来自COVID患者的含抗体的血清在中和该变体方面的效力明显较低。在1月26日发布的另一个初步预印本中，科学家报告称他们将B.1.351放入了接受过辉瑞或Moderna疫苗接种的人的血清中。他们发现，与抗原始病毒的活性相比，血清中的抗体对突变体的中和活性降低。</p><p> Antibodies in test tubes are not the same thing as vaccines in real people, however. Both vaccines produce so many antibodies that a drop in activity could still leave enough of them to neutralize the virus. The vaccines also stimulate other protective components of the immune system. Still, Moderna has begun work on a booster shot specific to new variants.</p><p> 但是，试管中的抗体与真实人中的疫苗不是同一回事。两种疫苗都产生如此多的抗体，以至于活性下降仍可能留下足够的抗体来中和病毒。疫苗还刺激免疫系统的其他保护性成分。尽管如此，Moderna仍已开始着手针对新变种的助推器射击。</p><p>     In January researchers reported they had detected two new variants in Brazil, both descendants of a somewhat older common ancestor variant. Although they share mutations with other newly discovered versions, they appear to have arisen independently of those variants.</p><p>     一月份的研究人员报告说，他们在巴西发现了两个新的变种，都是较古老的祖先变种的后代。尽管它们与其他新发现的版本共享突变，但它们似乎独立于那些变体而出现。</p><p> Of the two, researchers are currently  more concerned about P.1. That variant contains more  mutations than P.2 (though both have E484K), and it has already been seen in Japan and other countries. Although it is possible that P.1 accumulated its mutations in an immunocompromised individual, genetics researcher Emma Hodcroft of the University of Bern in Switzerland says that it might be more difficult to pinpoint the time and place when this variant first arose because Brazil does not sequence nearly as many viral samples as the U.K.</p><p> 在这两者中，研究人员目前更关注P.1。该变体比P.2包含更多的突变（尽管两者都具有E484K），并且已经在日本和其他国家/地区看到过。尽管P.1可能会在免疫受损的个体中积累其突变，但瑞士伯尔尼大学的遗传学研究人员Emma Hodcroft表示，由于巴西没有测序，可能很难确定这种变异首次出现的时间和地点。几乎与英国一样多的病毒样本</p><p> Hodcroft points out that both Brazil and South Africa had large COVID outbreaks in 2020. With so many infected people creating antibodies against the virus, a version that could evade the immune system and reinfect a person who had recovered might have a strong advantage and then become more widespread in a population.</p><p> Hodcroft指出，巴西和南非都将在2020年爆发大规模COVID。由于感染的人数量众多，他们都在产生针对该病毒的抗体，因此这种可以逃避免疫系统并重新感染已康复者的病毒可能具有强大的优势，然后成为在人口中更为普遍。</p><p>   Although the seemingly sudden emergence of several spike protein variants is reason for concern, researchers say there is no evidence that the virus has changed in a fundamental way that lets it mutate more rapidly. What is most likely, Lauring says, is that the sheer number of COVID cases worldwide is allowing the virus numerous opportunities to change a little bit. Each infected person is, essentially, a chance for SARS-CoV-2 to reinvent itself. “Some of it is evolution, but a lot of it is epidemiology,” Lauring says. Overall, “the virus is getting better at being a virus.”</p><p>   尽管似乎突然出现了几种刺突蛋白变体是引起关注的原因，但研究人员表示，没有证据表明该病毒已经以一种基本的方式发生了改变，从而使其能够更快地突变。 Lauring说，最有可能的是，全世界COVID病例的数量之多，使该病毒具有许多改变的机会。本质上，每个感染者都有机会重新感染SARS-CoV-2。劳林说：“其中有些是进化，但很多是流行病学。”总体而言，“该病毒越来越擅长成为病毒。” </p><p> Read more about the coronavirus outbreak from Scientific American   here. And read coverage from our international network of magazines  here.</p><p>在此处阅读更多有关《科学美国人》中冠状病毒爆发的信息。 并在此处阅读我们国际杂志网络的报道。 </p></div><div id="story_share_this"><div class="sharethis-inline-share-buttons"></div></div><div class="text-break sotry_link page_narrow"><a target="_blank" href="https://www.scientificamerican.com/article/the-most-worrying-mutations-in-five-emerging-coronavirus-variants/">https://www.scientificamerican.com/article/the-most-worrying-mutations-in-five-emerging-coronavirus-variants/</a></div><div class="story_tags page_narrow"><button type="button" class="btn btn-light my_tag"><a href="/tag/病毒/">#病毒</a></button><button type="button" class="btn btn-light my_tag"><a href="/tag/冠状病毒/">#冠状病毒</a></button><button type="button" class="btn btn-light my_tag"><a href="/tag/mutations/">#mutations</a></button></div></div><div class="my_movie_list_item shadow p-3 mb-5 bg-white rounded"><button type="button" class="btn btn-link my_tag"><a href="/tag/web2.0/">#web2.0</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/google/">#google</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/设计/">#设计</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/创意/">#创意</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/摄影/">#摄影</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/图片/">#图片</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/游戏/">#游戏</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/软件/">#软件</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/视频/">#视频</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/手机/">#手机</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/广告/">#广告</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/iphone/">#iphone</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/网站/">#网站</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/免费/">#免费</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/下载/">#下载</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/windows/">#windows</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/微软/">#微软</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/blog/">#blog</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/firefox/">#firefox</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/apple/">#apple</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/音乐/">#音乐</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/苹果/">#苹果</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/博客/">#博客</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/wordpress/">#wordpress</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/恶搞/">#恶搞</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/艺术/">#艺术</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/qq/">#qq</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/web/">#web</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/工具/">#工具</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/分享/">#分享</a></button></div></div></div><div id="my_footer"><div class=""><a href="/tags/">tags</a> <a href="/users/">users</a></div>&copy; 2020 diglog.com </div></div></body></html>